The statute itself is silent on what constitutes essentially copies of a commercially available drug product, but the FDA has interpretated the term broadly
The American Diabetes Associations 2024 Standards of Care recommend considering GLP-1 receptor agonists when metformin, with or without insulin, no longer achieves glycemic goals
Analysis of GLP-1 side effects reported to the US FDA suggest an increased reporting of various eye disorders across both patients with diabetes and those without
Why Its Added: GLP-1 medications can occasionally contribute to vitamin deficiencies with long-term use
Kempin, S, Arlin Z, Berman E, Gee T, Mertelsmann R, Andreeff M , Kolitz J, Jhanwar S, Meyers J, Clarkson B